UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No.     )*

 

Anika Therapeutics, Inc.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

035255108

(CUSIP Number)

 

December 31, 2007

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-1(b)

o

Rule 13d-1(c)

x

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 


 

CUSIP No. 035255108

 

 

1.

Names of Reporting Persons
Charles H. Sherwood

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
United States of America

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:

5.

Sole Voting Power
624,250

 

6.

Shared Voting Power
0

 

7.

Sole Dispositive Power
624,250

 

8.

Shared Dispositive Power
0

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
624,250

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

 

11.

Percent of Class Represented by Amount in Row (9)
5.6%

 

 

12.

Type of Reporting Person (See Instructions)
IN

 

 

2


 

Item 1.

 

(a)

Name of Issuer:

Anika Therapeutics, Inc. (the “Issuer”)

 

(b)

Address of Issuer’s Principal Executive Offices:

32 Wiggins Ave., Bedford, MA 01730

 

Item 2.

 

(a)

Name of Person Filing:

Charles H. Sherwood

 

(b)

Address of Principal Business Office or, if none, Residence:

c/o Anika Therapeutics, Inc.
32 Wiggins Ave.

Bedford, MA 01730

 

(c)

Citizenship:

United States of America

 

(d)

Title of Class of Securities:

Common Stock (the “Common Stock”)

 

(e)

CUSIP Number:

035255108

 

Item 3.

Not Applicable

 

Item 4.

Ownership

 

(a)

Amount beneficially owned:   

624,250

 

(b)

Percent of class:   

5.6%

 

(c)

Number of shares as to which the person has:

 

 

 

(i)

Sole power to vote or to direct the vote   

624,250

 

 

(ii)

Shared power to vote or to direct the vote    

0

 

 

(iii)

Sole power to dispose or to direct the disposition of   

624,250

 

 

(iv)

Shared power to dispose or to direct the disposition of   

0

 

 

3


 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   o.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

 

Item 8.

Identification and Classification of Members of the Group

Not applicable

 

Item 9.

Notice of Dissolution of Group

Not applicable

 

Item 10.

Certification

Not applicable

 

 

4


 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

February 14, 2008

 

Date

 


/s/ Charles H. Sherwood

 

Signature

 


Charles H. Sherwood/President and Chief Executive Officer

 

Name/Title

 

 

5